vs
亚什兰（ASH）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是Orthofix Medical Inc.的1.8倍（$386.0M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -3.1%，领先2.1%），Orthofix Medical Inc.同比增速更快（2.0% vs -4.7%），亚什兰自由现金流更多（$111.0M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ASH vs OFIX — 直观对比
营收规模更大
ASH
是对方的1.8倍
$219.9M
营收增速更快
OFIX
高出6.7%
-4.7%
净利率更高
OFIX
高出2.1%
-3.1%
自由现金流更多
ASH
多$94.2M
$16.8M
两年增速更快
OFIX
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $219.9M |
| 净利润 | $-12.0M | $-2.2M |
| 毛利率 | 27.2% | 71.1% |
| 营业利润率 | -1.6% | 0.2% |
| 净利率 | -3.1% | -1.0% |
| 营收同比 | -4.7% | 2.0% |
| 净利润同比 | 92.7% | 92.4% |
| 每股收益（稀释后） | $-0.26 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHOFIX
| Q4 25 | $386.0M | $219.9M | ||
| Q3 25 | $477.0M | $205.6M | ||
| Q2 25 | $463.0M | $203.1M | ||
| Q1 25 | $479.0M | $193.6M | ||
| Q4 24 | $405.0M | $215.7M | ||
| Q3 24 | $521.0M | $196.6M | ||
| Q2 24 | $544.0M | $198.6M | ||
| Q1 24 | $575.0M | $188.6M |
净利润ASHOFIX
| Q4 25 | $-12.0M | $-2.2M | ||
| Q3 25 | $31.0M | $-22.8M | ||
| Q2 25 | $-742.0M | $-14.1M | ||
| Q1 25 | $31.0M | $-53.1M | ||
| Q4 24 | $-165.0M | $-29.1M | ||
| Q3 24 | $17.0M | $-27.4M | ||
| Q2 24 | $6.0M | $-33.4M | ||
| Q1 24 | $120.0M | $-36.0M |
毛利率ASHOFIX
| Q4 25 | 27.2% | 71.1% | ||
| Q3 25 | 33.3% | 72.2% | ||
| Q2 25 | 28.5% | 68.7% | ||
| Q1 25 | 30.7% | 62.8% | ||
| Q4 24 | 27.4% | 69.0% | ||
| Q3 24 | 33.2% | 68.7% | ||
| Q2 24 | 34.2% | 67.8% | ||
| Q1 24 | 28.0% | 67.5% |
营业利润率ASHOFIX
| Q4 25 | -1.6% | 0.2% | ||
| Q3 25 | 12.8% | -8.3% | ||
| Q2 25 | -152.9% | -7.9% | ||
| Q1 25 | 10.6% | -25.2% | ||
| Q4 24 | -44.2% | -5.3% | ||
| Q3 24 | 6.1% | -9.6% | ||
| Q2 24 | -11.2% | -12.5% | ||
| Q1 24 | 3.7% | -15.6% |
净利率ASHOFIX
| Q4 25 | -3.1% | -1.0% | ||
| Q3 25 | 6.5% | -11.1% | ||
| Q2 25 | -160.3% | -6.9% | ||
| Q1 25 | 6.5% | -27.4% | ||
| Q4 24 | -40.7% | -13.5% | ||
| Q3 24 | 3.3% | -13.9% | ||
| Q2 24 | 1.1% | -16.8% | ||
| Q1 24 | 20.9% | -19.1% |
每股收益（稀释后）ASHOFIX
| Q4 25 | $-0.26 | $-0.05 | ||
| Q3 25 | $0.83 | $-0.57 | ||
| Q2 25 | $-16.21 | $-0.36 | ||
| Q1 25 | $0.65 | $-1.35 | ||
| Q4 24 | $-3.50 | $-0.76 | ||
| Q3 24 | $0.34 | $-0.71 | ||
| Q2 24 | $0.12 | $-0.88 | ||
| Q1 24 | $2.39 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $82.0M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $1.9B | $450.0M |
| 总资产 | $4.5B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资ASHOFIX
| Q4 25 | $304.0M | $82.0M | ||
| Q3 25 | $215.0M | $62.9M | ||
| Q2 25 | $207.0M | $65.6M | ||
| Q1 25 | $168.0M | $58.0M | ||
| Q4 24 | $219.0M | $83.2M | ||
| Q3 24 | $300.0M | $30.1M | ||
| Q2 24 | $399.0M | $26.4M | ||
| Q1 24 | $439.0M | $27.0M |
总债务ASHOFIX
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $157.2M | ||
| Q2 25 | $1.4B | $157.0M | ||
| Q1 25 | $1.3B | $156.9M | ||
| Q4 24 | $1.3B | $157.0M | ||
| Q3 24 | $1.3B | $118.5M | ||
| Q2 24 | $1.3B | $118.0M | ||
| Q1 24 | $1.3B | $118.2M |
股东权益ASHOFIX
| Q4 25 | $1.9B | $450.0M | ||
| Q3 25 | $1.9B | $442.5M | ||
| Q2 25 | $1.9B | $458.3M | ||
| Q1 25 | $2.6B | $458.3M | ||
| Q4 24 | $2.6B | $503.1M | ||
| Q3 24 | $2.9B | $525.9M | ||
| Q2 24 | $3.0B | $546.0M | ||
| Q1 24 | $3.1B | $570.3M |
总资产ASHOFIX
| Q4 25 | $4.5B | $850.6M | ||
| Q3 25 | $4.6B | $832.6M | ||
| Q2 25 | $4.6B | $837.2M | ||
| Q1 25 | $5.2B | $823.1M | ||
| Q4 24 | $5.2B | $893.3M | ||
| Q3 24 | $5.6B | $867.9M | ||
| Q2 24 | $5.7B | $882.0M | ||
| Q1 24 | $5.9B | $906.0M |
负债/权益比ASHOFIX
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.73× | 0.36× | ||
| Q2 25 | 0.73× | 0.34× | ||
| Q1 25 | 0.52× | 0.34× | ||
| Q4 24 | 0.51× | 0.31× | ||
| Q3 24 | 0.47× | 0.23× | ||
| Q2 24 | 0.45× | 0.22× | ||
| Q1 24 | 0.42× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 28.8% | 7.6% |
| 资本支出强度资本支出/营收 | 3.6% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $200.0M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ASHOFIX
| Q4 25 | $125.0M | $27.7M | ||
| Q3 25 | $40.0M | $12.4M | ||
| Q2 25 | $115.0M | $11.6M | ||
| Q1 25 | $9.0M | $-18.4M | ||
| Q4 24 | $-30.0M | $23.7M | ||
| Q3 24 | $80.0M | $11.7M | ||
| Q2 24 | $127.0M | $9.0M | ||
| Q1 24 | $54.0M | $-18.6M |
自由现金流ASHOFIX
| Q4 25 | $111.0M | $16.8M | ||
| Q3 25 | $6.0M | $2.5M | ||
| Q2 25 | $95.0M | $4.5M | ||
| Q1 25 | $-12.0M | $-25.1M | ||
| Q4 24 | $-53.0M | $15.2M | ||
| Q3 24 | $42.0M | $6.3M | ||
| Q2 24 | $98.0M | $-360.0K | ||
| Q1 24 | $20.0M | $-29.1M |
自由现金流率ASHOFIX
| Q4 25 | 28.8% | 7.6% | ||
| Q3 25 | 1.3% | 1.2% | ||
| Q2 25 | 20.5% | 2.2% | ||
| Q1 25 | -2.5% | -13.0% | ||
| Q4 24 | -13.1% | 7.0% | ||
| Q3 24 | 8.1% | 3.2% | ||
| Q2 24 | 18.0% | -0.2% | ||
| Q1 24 | 3.5% | -15.4% |
资本支出强度ASHOFIX
| Q4 25 | 3.6% | 4.9% | ||
| Q3 25 | 7.1% | 4.8% | ||
| Q2 25 | 4.3% | 3.5% | ||
| Q1 25 | 4.4% | 3.5% | ||
| Q4 24 | 5.7% | 4.0% | ||
| Q3 24 | 7.3% | 2.7% | ||
| Q2 24 | 5.3% | 4.7% | ||
| Q1 24 | 5.9% | 5.6% |
现金转化率ASHOFIX
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | — | ||
| Q1 24 | 0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
